Clinical trials
Metastatic Solid Tumor clinical trials
Below are recruiting metastatic solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+ - NCT05733949RecruitingEarly Phase 1
Targeted radiation for people with many solid tumor metastases
This trial tests a precise type of radiation that targets multiple tumor spots in a carefully planned way. It may help people with many metastatic (spread) solid tumors when standard treatments aren’t working or can’t be used.
Duarte, CaliforniaAges 18 years+ - NCT05741242Enrolling by invitationPhase 1/Phase 2
Vaccine trial using customized immune targets for solid tumors
This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.
Beverly Hills, CaliforniaAges 12 years+ - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT05688605RecruitingPhase 1/Phase 2
Study of MRG003 for EGFR-positive advanced cancers
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
Guangzhou, GuangdongAges 18–75 - NCT05689853RecruitingPhase 1/Phase 2
Testing two targeted cancer drugs for advanced solid tumors
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
Beijing, Beijing MunicipalityAges 18–75 - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT05661201RecruitingPhase 1
Testing a KRAS drug and doxorubicin for certain solid tumors
This Phase 1 study tests a drug called NEROFE together with doxorubicin in people whose tumors have a specific KRAS mutation and show ST2 in tumor tissue. It’s meant to find the safest dose and whether the treatment can shrink or control these advanced cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05631964RecruitingPhase 1
Early trial of BL-M07D1 for advanced HER2-positive digestive tumors
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05470348RecruitingPhase 1
Test drug BL-B01D1 for advanced breast and other solid cancers
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
Guangzhou, GuangdongAges 18–75 - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT05458219RecruitingPhase 1
Testing an antibody-drug treatment for solid tumors
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
Austin, TexasAges 18 years+ - NCT05430373RecruitingPhase 1
Injection study for advanced solid tumors using tumor-fighting cells
This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.
Beijing, Beijing MunicipalityAges 18–70 - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic solid tumor?
- Yes. Clin2 currently lists 1,100 recruiting metastatic solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.